Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication

Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication

Diabetes is a group of metabolic disorders that is characterized by hyperglycemia which increases the risks of cardiovascular, microvascular, and macrovascular complications. Innovative therapeutic trials regarding diabetes control and management are continually being undertaken. The present review...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biological regulators and homeostatic agents 2020-02, Vol.34 (1)
Hauptverfasser: Bhadel, P, Shrestha, S, Sapkota, B, Li, J Y, Tao, H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title Journal of biological regulators and homeostatic agents
container_volume 34
creator Bhadel, P
Shrestha, S
Sapkota, B
Li, J Y
Tao, H
description Diabetes is a group of metabolic disorders that is characterized by hyperglycemia which increases the risks of cardiovascular, microvascular, and macrovascular complications. Innovative therapeutic trials regarding diabetes control and management are continually being undertaken. The present review was aimed to explore the potential effects and mechanisms that lead to the pathogenesis of type 2 diabetes mellitus (T2DM) and its relation with asprosin. Asprosin is a newly discovered hormone that is encoded by protein fibrillin 1 (FBN1 gene), secreted by white adipose during fasting conditions at 5-10 nM levels, which acts on the liver through cell membrane receptors and activates the G protein cAMP- PKA pathway. Asprosin secretion is increased during fasting as the compensatory mechanism in hypoglycemia. Asprosin concentration is higher in patients with T2DM and impaired glucose regulation compared to healthy subjects. Genetic deficiency of asprosin may cause problems of poor appetite and extreme leanness in humans. Attenuating asprosin activity or depleting asprosin may serve as a novel therapeutic innovation for the treatment of T2DM and obesity. Hence, asprosin may serve as a beacon for the target of a future therapy in diabetes management.
doi_str_mv 10.23812/19-244-E
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2363066780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2363066780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c291t-2ed90b452db9312e91c1000cddd513f1e09b1ebb19013a886260f182e8e7ec843</originalsourceid><addsrcrecordid>eNo1kEtLAzEURrNQbK0u_AOSpZvRe5N0JnFXSn1AQRcK7oY8bjEyLycZof_egnX1bQ4fh8PYFcKtkBrFHZpCKFVsTtgcpJGFqdTHjJ2n9AWgpKqqMzaTAjQYs5yz11Uaxj7Fjtsu8LwfiAseonWUKfGWmibmKd1zy7v-hxo-9Jm6HG3D8yeNdqApR89jOzTR2xz77oKd7myT6PK4C_b-sHlbPxXbl8fn9WpbeGEwF4KCAaeWIjgjUZBBjwDgQwhLlDskMA7JOTSA0mpdihJ2qAVpqshrJRfs5u_3oP89Ucp1G5M_-NqO-inVQpYSyrLScECvj-jkWgr1MMbWjvv6v4L8BdPYW3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2363066780</pqid></control><display><type>article</type><title>Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Bhadel, P ; Shrestha, S ; Sapkota, B ; Li, J Y ; Tao, H</creator><creatorcontrib>Bhadel, P ; Shrestha, S ; Sapkota, B ; Li, J Y ; Tao, H</creatorcontrib><description>Diabetes is a group of metabolic disorders that is characterized by hyperglycemia which increases the risks of cardiovascular, microvascular, and macrovascular complications. Innovative therapeutic trials regarding diabetes control and management are continually being undertaken. The present review was aimed to explore the potential effects and mechanisms that lead to the pathogenesis of type 2 diabetes mellitus (T2DM) and its relation with asprosin. Asprosin is a newly discovered hormone that is encoded by protein fibrillin 1 (FBN1 gene), secreted by white adipose during fasting conditions at 5-10 nM levels, which acts on the liver through cell membrane receptors and activates the G protein cAMP- PKA pathway. Asprosin secretion is increased during fasting as the compensatory mechanism in hypoglycemia. Asprosin concentration is higher in patients with T2DM and impaired glucose regulation compared to healthy subjects. Genetic deficiency of asprosin may cause problems of poor appetite and extreme leanness in humans. Attenuating asprosin activity or depleting asprosin may serve as a novel therapeutic innovation for the treatment of T2DM and obesity. Hence, asprosin may serve as a beacon for the target of a future therapy in diabetes management.</description><identifier>ISSN: 0393-974X</identifier><identifier>DOI: 10.23812/19-244-E</identifier><identifier>PMID: 32080995</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Journal of biological regulators and homeostatic agents, 2020-02, Vol.34 (1)</ispartof><rights>Copyright 2020 Biolife Sas. www.biolifesas.org.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c291t-2ed90b452db9312e91c1000cddd513f1e09b1ebb19013a886260f182e8e7ec843</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32080995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhadel, P</creatorcontrib><creatorcontrib>Shrestha, S</creatorcontrib><creatorcontrib>Sapkota, B</creatorcontrib><creatorcontrib>Li, J Y</creatorcontrib><creatorcontrib>Tao, H</creatorcontrib><title>Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication</title><title>Journal of biological regulators and homeostatic agents</title><addtitle>J Biol Regul Homeost Agents</addtitle><description>Diabetes is a group of metabolic disorders that is characterized by hyperglycemia which increases the risks of cardiovascular, microvascular, and macrovascular complications. Innovative therapeutic trials regarding diabetes control and management are continually being undertaken. The present review was aimed to explore the potential effects and mechanisms that lead to the pathogenesis of type 2 diabetes mellitus (T2DM) and its relation with asprosin. Asprosin is a newly discovered hormone that is encoded by protein fibrillin 1 (FBN1 gene), secreted by white adipose during fasting conditions at 5-10 nM levels, which acts on the liver through cell membrane receptors and activates the G protein cAMP- PKA pathway. Asprosin secretion is increased during fasting as the compensatory mechanism in hypoglycemia. Asprosin concentration is higher in patients with T2DM and impaired glucose regulation compared to healthy subjects. Genetic deficiency of asprosin may cause problems of poor appetite and extreme leanness in humans. Attenuating asprosin activity or depleting asprosin may serve as a novel therapeutic innovation for the treatment of T2DM and obesity. Hence, asprosin may serve as a beacon for the target of a future therapy in diabetes management.</description><issn>0393-974X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo1kEtLAzEURrNQbK0u_AOSpZvRe5N0JnFXSn1AQRcK7oY8bjEyLycZof_egnX1bQ4fh8PYFcKtkBrFHZpCKFVsTtgcpJGFqdTHjJ2n9AWgpKqqMzaTAjQYs5yz11Uaxj7Fjtsu8LwfiAseonWUKfGWmibmKd1zy7v-hxo-9Jm6HG3D8yeNdqApR89jOzTR2xz77oKd7myT6PK4C_b-sHlbPxXbl8fn9WpbeGEwF4KCAaeWIjgjUZBBjwDgQwhLlDskMA7JOTSA0mpdihJ2qAVpqshrJRfs5u_3oP89Ucp1G5M_-NqO-inVQpYSyrLScECvj-jkWgr1MMbWjvv6v4L8BdPYW3Q</recordid><startdate>20200221</startdate><enddate>20200221</enddate><creator>Bhadel, P</creator><creator>Shrestha, S</creator><creator>Sapkota, B</creator><creator>Li, J Y</creator><creator>Tao, H</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20200221</creationdate><title>Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication</title><author>Bhadel, P ; Shrestha, S ; Sapkota, B ; Li, J Y ; Tao, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c291t-2ed90b452db9312e91c1000cddd513f1e09b1ebb19013a886260f182e8e7ec843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhadel, P</creatorcontrib><creatorcontrib>Shrestha, S</creatorcontrib><creatorcontrib>Sapkota, B</creatorcontrib><creatorcontrib>Li, J Y</creatorcontrib><creatorcontrib>Tao, H</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biological regulators and homeostatic agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhadel, P</au><au>Shrestha, S</au><au>Sapkota, B</au><au>Li, J Y</au><au>Tao, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication</atitle><jtitle>Journal of biological regulators and homeostatic agents</jtitle><addtitle>J Biol Regul Homeost Agents</addtitle><date>2020-02-21</date><risdate>2020</risdate><volume>34</volume><issue>1</issue><issn>0393-974X</issn><abstract>Diabetes is a group of metabolic disorders that is characterized by hyperglycemia which increases the risks of cardiovascular, microvascular, and macrovascular complications. Innovative therapeutic trials regarding diabetes control and management are continually being undertaken. The present review was aimed to explore the potential effects and mechanisms that lead to the pathogenesis of type 2 diabetes mellitus (T2DM) and its relation with asprosin. Asprosin is a newly discovered hormone that is encoded by protein fibrillin 1 (FBN1 gene), secreted by white adipose during fasting conditions at 5-10 nM levels, which acts on the liver through cell membrane receptors and activates the G protein cAMP- PKA pathway. Asprosin secretion is increased during fasting as the compensatory mechanism in hypoglycemia. Asprosin concentration is higher in patients with T2DM and impaired glucose regulation compared to healthy subjects. Genetic deficiency of asprosin may cause problems of poor appetite and extreme leanness in humans. Attenuating asprosin activity or depleting asprosin may serve as a novel therapeutic innovation for the treatment of T2DM and obesity. Hence, asprosin may serve as a beacon for the target of a future therapy in diabetes management.</abstract><cop>Italy</cop><pmid>32080995</pmid><doi>10.23812/19-244-E</doi></addata></record>
fulltext fulltext
identifier ISSN: 0393-974X
ispartof Journal of biological regulators and homeostatic agents, 2020-02, Vol.34 (1)
issn 0393-974X
language eng
recordid cdi_proquest_miscellaneous_2363066780
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A07%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asprosin%20and%20type%202%20diabetes%20mellitus:%20a%20novel%20potential%20therapeutic%20implication&rft.jtitle=Journal%20of%20biological%20regulators%20and%20homeostatic%20agents&rft.au=Bhadel,%20P&rft.date=2020-02-21&rft.volume=34&rft.issue=1&rft.issn=0393-974X&rft_id=info:doi/10.23812/19-244-E&rft_dat=%3Cproquest_pubme%3E2363066780%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2363066780&rft_id=info:pmid/32080995&rfr_iscdi=true